A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Safety and Tolerability of Tacrolimus in Stable Kidney Transplant Patients Converted From a Prograf [tacrolimus] Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen.
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2013
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Sponsors Astellas Pharma; Astellas Pharma US
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2009 Planned patient number added (68) as reported by ClinicalTrials.gov.
- 08 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.